61% of Hong Kong Women are Concerned About Current Body Shape
HONG KONG, July 11, 2013
HONG KONG, July 11, 2013 /PRNewswire/ --
Syneron Medical, a Global Leader in devices for aesthetic medicine to present
latest technologies to meet growing demands for enhanced body beauty at 9 ^th
Asian Dermatological Congress in Hong Kong
Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device
company, announced today, during the 9 ^th Asian Dermatological Congress, the
results of a recent survey on body shaping among Asian populations as well as
the latest technologies allowing for best in class, non-invasive, energy based
solutions for body shaping indications.
(Logo: http://photos.prnewswire.com/prnh/20120528/535447 )
61% of Hong Kong women dissatisfied with their current body shape
A recent survey sponsored by Syneron and conducted by The Nielsen Company,
inApril andMay of 2013, showed that while looking good is extremely
important to Asian women (49% in Hong Kong alone), a vast majority of Asian
women in Hong Kong, Taiwan and Australia are concerned by their body shape. Up
to 75% (46% in Australia, 61% in Hong Kong and 75% in Taiwan) of the 500 women
surveyed in each country, aged 25 to 49, said that they were dissatisfied with
their current body shape. Women expressing these dissatisfactions were mainly
single in Hong Kong and Taiwan, while in Australia, the highest number of
concerned women were married. According to the survey the most common body
shape concerns include love handles orbra fat and tummy bulge. Among them,
love handlesor bra fat andtummy bulge are at the top of the list in all
three countries with over 49% of the respondents claiming these physical signs
to be key concerns.
"These numbers clearly show what we are experiencing in our clinic," confirms
Prof. Henry Chan, renowned Hong Kong specialist in dermatology. "With the
growing demand for body shaping solutions among Asians, we need to pay
particular attention to potential issues of post inflammatory
hyperpigmentation lesions that can come from treatments that may be too
aggressive." TheUltraShape® technology is of great interest because it
provides visible results without these types of safety risks. Prof. Chan will
be conducting a clinical trialto specifically identify the additional
benefits of UltraShape relative to fat cell destruction in Asian populations.
Syneron committed to supporting body contouring market dynamics
"Customer satisfaction, patient safety and minimal downtime represent our
absolute priorities", confirmed Shimon Eckhouse, PhD, co-founder and Chief
Executive Officer of Syneron Medical Ltd. "We are passionate about our science
and the results we can achieve with our VelaShape , non-invasive
circumferential reduction and cellulite treatment technology and with our
UltraShape non-invasive fat destruction technology. These technologies and our
continuous investment in their improvement build our customer trust and the
confidence in our brands." A 2012 Global Aesthetic Market research report
from Medical Insight, Inc. confirms that body shaping and skin tightening will
continue to drive the multi-billion dollar growth of the aesthetic market.
Syneron has allocated specific resources to this particular market segment
with targeted research & development activities and new upgrades for its two
main body shaping platforms, VelaShape™ and UltraShape ®.
In his presentation of the unique features of these two different
technologies, Dr. Robert Weiss, Vice President of the American Society for
Lasers in Medicine and Surgery, mentioned "we are quite pleased to see how
these services are providing women with visible results and increased
self-confidence. Doctors have been able to reach a significant reduction of
centimeters in circumference with VelaShape and the pulsed focused ultrasound
technology of the UltraShape system is allowing patients to get rid of
localized fat deposits with no swelling, bruising or downtime. "
Two unique, safe and effective technologies
UltraShape is the only non-invasive, painless non-thermal and non-surgical
procedure that instantly and selectively destroys fat cells alone, allowing
their contents to then be processed by the body's natural physiological and
VelaShape is a medical device based on the combination of four technologies
including the revolutionary elos combination of bipolar radiofrequency (RF)
and infrared light energy plus vacuum and mechanical massage. It is the first
FDA cleared device for treatment of cellulite and circumferential reduction of
About Syneron Medical Ltd.
Syneron Medical Ltd. (NASDAQ: ELOS ) is the leading global aesthetic device
company with a comprehensive product portfolio and a global distribution
footprint. The Company's technology enables physicians to provide advanced
solutions for a broad range of medical-aesthetic applications including body
contouring, hair removal, wrinkle reduction, rejuvenation of the skin's
appearance through the treatment of superficial benign vascular and pigmented
lesions, and the treatment of acne, leg veins and cellulite. The Company sells
its products under two distinct brands, Syneron and Candela. Founded in 2000,
the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd.
are located in Israel. Syneron also has R&D and manufacturing operations in
the US. The Company markets, services and supports its products in 90
countries. It has offices in North America, France, Germany, Italy, Portugal,
Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
Safe Harbor for Forward-looking Statements
Any statements contained in this document regarding future expectations,
beliefs, goals, plans or prospects constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Further, any statements that are not statements of historical fact (including
statements containing "believes," "anticipates," "plans," "expects," "may,"
"will," "would," "intends," "estimates" and similar expressions) should also
be considered to be forward-looking statements. There are a number of
important factors that could cause actual results or events to differ
materially from those indicated by such forward-looking statements, such as
the company's ability to effectively market the new enhancements, as well as
the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on
Form 20-F, and the other factors described in the filings that Syneron Medical
Ltd. makes with the SEC from time to time. If one or more of these factors
materialize, or if any underlying assumptions prove incorrect, Syneron Medical
Ltd.'s actual results, performance or achievements may vary materially from
any future results, performance or achievements expressed or implied by these
In addition, the statements in this document reflect the expectations and
beliefs of Syneron Medical Ltd. as of the date of this document. Syneron
Medical Ltd. anticipates that subsequent events and developments will cause
its expectations and beliefs to change. However, while Syneron Medical Ltd.
may elect to update these forward-looking statements publicly in the future,
it specifically disclaims any obligation to do so. The forward-looking
statements of Syneron Medical Ltd. do not reflect the potential impact of any
future dispositions or strategic transactions that may be undertaken. These
forward-looking statements should not be relied upon as representing Syneron
Medical Ltd.'s views as of any date after the date of this document.
Syneron Public Relations firstname.lastname@example.org
Syneron Investors Relations email@example.com
Hugo Goldman, Chief Financial Officer Email: firstname.lastname@example.org
Zack Kubow, The Ruth Group +1-646-536-7020 Email: email@example.com
Press spacebar to pause and continue. Press esc to stop.